CLYYF.US Celyad Oncology SA

Healthcare Biotechnology USA Stocks
0.2800 USD
Close of Nov 13, 2026
0.1500 0.3500
Market cap
USD 21.0M
P/E
3.1x
P/B
14.92x
ROE
-382.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CLYYF.US undervalued?

Graham number
Price0.2800
Graham value0.1950
Premium43.6%

CLYYF.US trades 43.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celyad Oncology SA fundamental analysis

No fundamental analysis for Celyad Oncology SA yet.

Celyad Oncology SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celyad Oncology SA

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Full company profile